Stock NAMS FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Frazier Lifesciences Acquisition Corporation Share Price

Equities

NAMS

NL00150012L7

Biotechnology & Medical Research

Real-time Estimate Tradegate
Other stock markets
 01:20:11 29/05/2024 am IST 		5-day change 1st Jan Change
18.05 EUR -5.50% Intraday chart for Frazier Lifesciences Acquisition Corporation -3.73% +70.99%
15/05 TD Cowen Starts NewAmsterdam Pharma With Buy Rating MT
09/05 Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M MT

Financials

Sales 2024 * 8.45M 9.17M 763M Sales 2025 * 6.3M 6.84M 569M Capitalization 1.56B 1.69B 141B
Net income 2024 * -208M -226M -18.78B Net income 2025 * -134M -146M -12.1B EV / Sales 2024 * 185 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 248 x
P/E ratio 2024 *
-7.51 x
P/E ratio 2025 *
-12 x
Employees 40
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.29%
More Fundamentals * Assessed data

Chart Frazier Lifesciences Acquisition Corporation

Dynamic Chart

Latest news about Frazier Lifesciences Acquisition Corporation

TD Cowen Starts NewAmsterdam Pharma With Buy Rating MT
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M MT
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease CI
NewAmsterdam Pharma Names Juliette Audet Chief Business Officer MT
Newamsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer CI
Newamsterdam Pharma Insider Sold Shares Worth $4,095,234, According to a Recent SEC Filing MT
Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target MT
Newamsterdam Pharma Company N.V. Doses First Patient in Phase 3 Tandem Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with Hefh And/Or Ascvd CI
Transcript : NewAmsterdam Pharma Company N.V. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 04:00 PM
RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk MT
NewAmsterdam Pharma Full Year 2023 Net Loss Widens, Revenue Drops MT
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
NewAmsterdam Pharma Prices $175.3 Million Public Offering MT
Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target MT
More news

Latest transcript on Frazier Lifesciences Acquisition Corporation

Logo Frazier Lifesciences Acquisition Corporation
NewAmsterdam Pharma Company N.V. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 04:00 PM
More transcripts

Analyst Recommendations on Frazier Lifesciences Acquisition Corporation

TD Cowen Starts NewAmsterdam Pharma With Buy Rating MT
Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target MT
RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk MT
Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target MT
RBC Initiates NewAmsterdam Pharma at Outperform With Speculative Risk Qualifier, $25 Price Target MT
More recommendations

Press releases Frazier Lifesciences Acquisition Corporation

NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings GL
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings AQ
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AQ
More press releases

Quotes and Performance

1 day-5.50%
1 week-3.73%
Current month-12.43%
1 month-13.14%
3 months-21.17%
6 months+93.71%
Current year+70.99%
More quotes

Highs and lows

1 week
18.51
Extreme 18.51
20.33
1 month
18.51
Extreme 18.51
23.01
Current year
11.18
Extreme 11.18
26.35
1 year
5.63
Extreme 5.6326
26.35
3 years
5.63
Extreme 5.6326
32.88
5 years
5.63
Extreme 5.6326
32.88
10 years
5.63
Extreme 5.6326
32.88
More quotes

Quotes

Date Price Change Volume
23/24/23 19.1 -2.45% 35 045
24/24/24 18.82 -1.47% 131,706
23/24/23 19.1 -2.45% 35,045
22/24/22 19.58 +0.51% 139,267
21/24/21 19.48 -1.81% 53,484

End-of-day quote Nasdaq, May 23, 2024

More quotes

Company Profile

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Sector
Biotechnology & Medical Research
Calendar
05:42pm - European Atherosclerosis Society Congress - Session Name: 0601
More about the company

Income Statement Evolution

More financial data

Ratings for Frazier Lifesciences Acquisition Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
17.34 EUR
Average target price
32.12 EUR
Spread / Average Target
+85.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
FRAZIER LIFESCIENCES ACQUISITION CORPORATION Stock Frazier Lifesciences Acquisition Corporation
+70.99% 1.69B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.86% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.40% 106B
BIONTECH SE Stock BioNTech SE
-11.15% 23.4B
ARGENX SE Stock argenx SE
-1.69% 22.1B
GENMAB A/S Stock Genmab A/S
-10.23% 18.34B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.92% 16.59B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.52% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.93% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+17.84% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NAMS Stock